A5011208775- CAR-T cell therapy research
- Childhood Cancer Survivors' Quality of Life
- Cancer survivorship and care
- Palliative Care and End-of-Life Issues
- Lymphoma Diagnosis and Treatment
- Cancer-related cognitive impairment studies
- Chronic Lymphocytic Leukemia Research
- Multiple Myeloma Research and Treatments
- Statistical Methods in Clinical Trials
- Acute Myeloid Leukemia Research
- Hematopoietic Stem Cell Transplantation
- Acute Lymphoblastic Leukemia research
- Health Systems, Economic Evaluations, Quality of Life
- Biomedical Ethics and Regulation
- Economic and Financial Impacts of Cancer
- Silicon Carbide Semiconductor Technologies
- Safe Handling of Antineoplastic Drugs
- Family Support in Illness
- Innovations in Medical Education
- COVID-19 and healthcare impacts
- Biosimilars and Bioanalytical Methods
- Clinical Reasoning and Diagnostic Skills
- Integrated Circuits and Semiconductor Failure Analysis
- Healthcare professionals’ stress and burnout
- Patient-Provider Communication in Healthcare
Harvard University
2021-2025
Massachusetts General Hospital
2021-2025
Newton Wellesley Hospital
2024
University of Washington
2015-2019
Seattle University
2017-2019
National Patient Safety Foundation
2019
Fred Hutch Cancer Center
2015
Abstract Chimeric antigen receptor T-cell therapy (CAR-T) has transformed the treatment for relapsed/refractory hematologic malignancies; however, data on patient-reported outcomes in CAR-T are limited. We conducted a longitudinal study of adults with malignancies receiving CAR-T. assessed quality life (QOL; functional assessment cancer therapy–general), psychological distress (hospital anxiety and depression scale, patient health questionnaire-9, posttraumatic stress disorder [PTSD]...
Abstract Background Chimeric antigen receptor (CAR) T‐cell is potentially curative therapy for patients with hematologic malignancies but can cause life‐threatening toxicities. Data on perceptions of prognosis and psychological distress are lacking. Methods The authors conducted a cross‐sectional study receiving CAR‐T. Before hospitalization CAR‐T, completed assessments quality life (QOL) (Functional Assessment Cancer Therapy‐General), anxiety depression symptoms (Hospital Anxiety Depression...
Background Social support is crucial for successful recovery after hematopoietic stem cell transplantation (HSCT) and has the potential to affect patient quality of life (QOL) health outcomes. However, there are limited data on relationship between a patient's perception his or her social these Methods The authors conducted secondary analysis 250 autologous allogeneic HSCT recipients enrolled in 2 supportive care trials at Massachusetts General Hospital from April 2011 through February 2016....
Background: CAR T-cell therapy has revolutionized the treatment of patients with hematologic malignancies, but it can result in prolonged hospitalizations and serious toxicities. However, data on impact healthcare utilization end-of-life (EoL) outcomes are lacking. Methods: We conducted a retrospective analysis 236 who received at 2 tertiary care centers from February 2016 through December 2019. abstracted EoL electronic health record, including hospitalizations, receipt ICU care,...
Patients diagnosed with acute myeloid leukemia (AML) face sudden-onset life-threatening disease that requires intensive treatments. Although their early trajectory is characterized by significant, toxic side effects, limited data are available describing coping strategies among patients AML and how these inform patient-reported outcomes. We used cross-sectional secondary analyses to describe in 160 newly high-risk AML. The Brief COPE, Hospital Anxiety Depression Scale, Post-Traumatic Stress...
Patients with acute myeloid leukemia (AML) face an abrupt life-threatening illness and experience immense physical psychological symptoms. However, no data describe how patients AML cope longitudinally their or the relationship between longitudinal coping outcomes.We conducted a secondary analysis of from 160 high-risk enrolled in supportive care intervention trial to strategies across course. We used Brief COPE questionnaire, Hospital Anxiety Depression Scale, Post-Traumatic Stress Disorder...
Hematopoietic cell transplantation (HCT) is a potentially curative therapy for hematologic malignancies, but it often results in significant toxicities and impaired quality of life (QOL). Although the value patient-reported outcomes (PROs) increasingly recognized HCT, data are limited regarding relationship between PROs HCT complications. We conducted secondary analysis 250 patients who were hospitalized autologous or allogeneic at Massachusetts General Hospital from 2011 through 2016....
Abstract Background Indolent non-Hodgkin’s lymphomas (iNHL) are a heterogenous group of mostly incurable diseases with prolonged illness courses and prognostic uncertainty. Yet, studies evaluating coping perception prognosis limited. Methods We conducted cross-sectional study adults newly diagnosed iNHL in the past 3 months at single academic center. assessed quality life (QOL: Functional Assessment Cancer Therapy—General), psychological symptoms (Hospital Anxiety Depression Scale),...
BackgroundIn relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) patients (pts) who had previously failed ibrutinib, we observed durable responses after CD19 chimeric antigen receptor-modified T-cell immunotherapy (Turtle CJ et al, JCO, 2017; NCT01865617). The combination of CAR-T cells with ibrutinib might improve response and decrease toxicity.ObjectivesTo evaluate the efficacy toxicity cell alone or in for R/R CLL.MethodsOur phase 1/2 study established a preferred regimen CLL pts...
Abstract Purpose Lymphoma is a health outcome of interest for drug safety studies. Studies using administrative claims data require the accurate identification lymphoma cases. We developed and validated an International Classification Diseases, Tenth Revision, Clinical Modification (ICD‐10‐CM)‐based algorithm to identify in healthcare data. Methods three‐component patients aged ≥15 years who were newly diagnosed with Hodgkin (HL) or non‐Hodgkin (NHL) from January 2016 through July 2018 among...
CAR T-cell therapy has transformed the treatment of hematologic malignancies, but it is complex and challenging to convey patients. Educational video interventions are efficacious for improving patient knowledge about cancer therapeutics informing their care preferences, yet no educational videos have been evaluated in therapy.
Little is known about serious illness conversations (SIC) conducted during telemedicine visits and their impact on end-of-life (EOL) outcomes for patients with advanced cancer.